SLC4A9

Across TCGA pan-cancer cohorts, SLC4A9 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC4A9 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SLC4A9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC4A9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, LIHC, and UCEC are the cancer types where SLC4A9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.501	0.688	<.001	32	view →
LIHC	OS	Median	All	0.051	0.775	<.001	24	view →
UCEC	DFS	Median	All	0.978	0.826	.008	24	view →
COAD	DFS	Median	All	0.134	0.794	<.001	21	view →
SKCM	DFS	Median	III,IV	0.177	0.517	.003	13	view →
ESCA	OS	Median	II,III,IV	0.206	0.686	.011	12	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC4A9–STAD (OS)

Open the STAD breakdown →